Vogt JA, Domzig C, Wabitsch M, Denzer C. Prehepatic secretion and disposal of insulin in obese adolescents as estimated by threehour, eight-sample oral glucose tolerance tests. Am J Physiol Endocrinol Metab 311: E82-E94, 2016. First published April 26, 2016 doi:10.1152/ajpendo.00455.2014.-The body compensates for earlystage insulin resistance by increasing insulin secretion. A reliable and easy-to-use mathematical assessment of insulin secretion and disposal could be a valuable tool for identifying patients at risk for the development of type 2 diabetes. Because the pathophysiology of insulin resistance is incompletely understood, assessing insulin metabolism with minimal assumptions regarding its metabolic regulation is a major challenge. To assess insulin secretion and indexes of insulin disposal, our marginalized and regularized absorption approach (MRA) was applied to a sparse sampling oral glucose tolerance test (OGTT) protocol measuring the insulin and C-peptide concentrations. Identifiability and potential bias of metabolic parameters were estimated from published data with dense sampling. The MRA was applied to OGTT data from 135 obese adolescents to demonstrate its clinical applicability. Individual prehepatic basal and dynamic insulin secretion and clearance levels were determined with a precision and accuracy greater than 10% of the nominal value. The intersubject variability in these parameters was approximately four times higher than the intrasubject variability, and there was a strong negative correlation between prehepatic secretion and plasma clearance of insulin. MRA-based analysis provides reliable estimates of insulin secretion and clearance, thereby enabling detailed glucose homeostasis characterization based on restricted datasets that are obtainable during routine patient care. modeling; insulin; C-peptide; MCMC simulation; bayesian analysis; OGTT INSULIN RESISTANCE IS THE HALLMARK FEATURE of a metabolically adverse phenotype in obese adults, children, and adolescents. The body can compensate for insulin resistance by increasing insulin secretion or decreasing insulin degradation (5, 14, 20) . This study explores insulin secretion and degradation under assumed prediabetic conditions in an at-risk population of markedly obese adolescents from oral glucose tolerance test (OGTT) data using a protocol with eight sampling points over three hours.
These formulas were calibrated using either intravenous glucose tolerance test data (24) or glucose clamp study data (50) from adult populations. However, the corresponding equations were neither designed nor validated for use in children and adolescents. Alternatively, insulin secretion can be determined using a "minimal model of C-peptide" based on measurements of insulin and C-peptide levels during an OGTT (3, 51, 54) . The minimal C-peptide model uses a mechanistic description of the static and dynamic effects of glucose on insulin secretion. Again, this approach has been rigorously validated only in adult populations and is currently being actively refined to assess the stimulatory effect of incretins on insulin secretion (55) . Corresponding results could be used to fine-tune "integrated models" that relate the incretin effect to the glucose concentration profile (4, 9) . However, these models have been established for adults only.
Comparably limited knowledge is available for insulin disposal. Tissue degradation involves insulin receptor binding (15) and the internalization and degradation of the insulinreceptor complex. In vitro data indicate a nonlinear insulin receptor binding curve (47) , and these results were confirmed in the liver (46) . In vivo hepatic insulin degradation is modulated by the portal concentrations of insulin (27) , glucose (41) , and free fatty acids (65) . Hepatic clearance removes 40 -80% of the secreted insulin (16, 19) . The integration of hepatic insulin clearance with peripheral insulin disposal in vivo is largely unknown.
In childhood and adolescence, insulin sensitivity undergoes significant physiological changes during pubertal development (22, 38) and even before the onset of puberty (26) . Moreover, even if the underlying mechanisms were established, the actual levels of the key factors controlling insulin levels were usually not measured in a routine manner. These uncertainties are barriers to the use of a paradigm of "parametric modeling"; here, a model based on established molecular mechanisms is proposed. Specific features of the model such as sensitivity and maximal capacity are captured by parameters that are determined by fitting the model prediction to measured data. A satisfactory fit to a redundant data set shows that the model can explain the data and can thereby partially validate the model. An example of the application of such a concept to insulin metabolism is the work of Silber et al. (48) . Considering the uncertainties concerning insulin secretion and hepatic insulin degradation, the initial validation of a parametric model is not applicable for sparsely sampled parameters, which could show fitness to any model structure. Hence, to avoid model misspeci-fication, insulin secretion and hepatic insulin disposal are modeled as time-dependent, "nonparametric" processes with shapes that are determined from data without any assumptions about molecular mechanisms. The time curves in question may have multiple peaks and inflection points, and the number of unknown coefficients necessary to capture features for two different processes may approach the number of measurement points. Secretion can be considered as an unknown input into a kinetic system that can be assessed via deconvolution. The restraint that the secretion curve should be as smooth as possible helps ameliorate the problem of having too many unknowns. This form of restraint is termed regularization and has been applied successfully to a combined deconvolutionregularization approach (13, 49) . We recently developed a marginalization and regularization approach (MRA) (58) , which assesses the time profile of an unknown secretion based on the plasma concentration of the released substance. The MRA defines the likelihood of observing a specific set of measured values as a function of a kinetic parameter and a parameter pertaining to the rigidity or stiffness of the release function (regularization). The likelihood can be optimized using sampling procedures to provide statistical features of the estimates, such as confidence ranges for individual estimates. Thus, both the deconvolution approach and the MRA could be used to assess the insulin secretion profile. Using either approach, the distribution and further metabolism of the secreted substance should be a linear function of the substance concentration. Linearity has been established for kinetic models of C-peptide (17, 57) .
On the basis of the C-peptide concentration, one could estimate insulin secretion and use this time profile to analyze insulin data using a separate model. Such a sequential approach was applied on insulin/C-peptide data collected with frequent or dense sampling (7) . However, with sparse sampling, measurement errors in C-peptide levels may distort the secretion profile and thereby bias the analysis of the insulin data, and the effect of measurement error on the final estimate is difficult to assess. Thus, a joint, simultaneous analysis of insulin and C-peptide data is preferred, such as the analysis performed by Watanabe et al. (61) . However, this approach restricts the insulin model to a linear system. This approach does not affect hepatic insulin disposal, which is modeled as a nonparametric, time-varying process, but a function of peripheral insulin disposal that is nonlinear could lead to model misspecification that cannot be detected by approaches based on a linear system. Therefore, we explored the impact of underlying nonlinearity in disposal and attempted to develop indexes that are robust against such nonlinearity. Whereas the degree of smoothing can be automatically controlled when insulin secretion is assessed as an unknown input into a kinetic system (49), these techniques cannot be used to assess the time course of hepatic insulin disposal. Nevertheless, we can still impose smoothness restraints and can require that hepatic and peripheral insulin disposal are of the same order of magnitude (19) . Recycling of insulin from the systemic circulation to the liver is mediated by liver blood flow, which is usually not measurable under conditions of clinical studies but can be estimated from literature data (8, 64) . Thus, there is abundant prior information about the mean values of coefficients describing these processes and resulting behavior, and such prior information can be used to more reliably estimate parameters by employing Bayesian statistics and techniques. The final estimates of insulin secretion and disposal thus reflect a compromise between prior allowances and values that lead to a best fit of the data. Bayesian approaches have been applied successfully to kinetic data pertaining to glucose/insulin interactions (6, 10, 21, 29) . We are not aware of any approach to assess insulin secretion and disposal using combined plasma insulin and C-peptide data derived from an OGTT with sparse sampling, which defines and employs a tolerable range for the kinetic coefficients involved. To resolve this issue, we used our recently developed MRA (58) , which can be easily embedded into a Bayesian analysis, to assign restraints to parameters and assess confidence ranges for any estimate. As a direct estimate, we predicted the time courses of insulin disposal and secretion. As these parameters are difficult to compare between different conditions or patients, a single number or surrogate index capturing the dynamics of insulin disposal and secretion was developed by integrating or averaging the time course of insulin levels over the test period.
The present study explored the applicability of our model to data from an OGTT with restricted sampling at eight time points. The sampling number exceeds the minimal requirement for the protocol presented by Cobelli et al. (11) but can still be performed during routine patient care when the structure of the model used for evaluation is validated. Under sparse sampling, nonparametric description may not reveal rapid changes in the evaluated processes and lead to a bias in the evaluated data. However, there are published population mean values for plasma insulin and C-peptide levels obtained from an OGTT with dense sampling (51) , and these data facilitate the assessment of sampling-induced bias, specifically for surrogate indexes. For this data set, insulin secretion can be assessed from C-peptide data alone. As the insulin secretion profile has already been estimated, the requirement for linearity can be removed for a separate model of insulin kinetics. The effect of nonlinearity in peripheral insulin disposal can be analyzed, and in turn, the results of this analysis can be used to assess potential model misspecification for peripheral insulin disposal. Upon establishment of the applicability of the model, this approach was used for retrospective evaluation of routine data collected in a population of obese adolescents. Further steps in the development of our approach will include testing whether the determination of insulin secretion parameters in an individual will be sufficiently precise for an individual classification of metabolic risk. An additional long-term aim is to establish an automatable evaluation approach that is combined with a sampling protocol that is sufficiently simple to be used during routine patient care.
METHODS
Proinsulin secretion contributes equal amounts to circulating insulin and C-peptide levels. The model shown in Fig. 1 uses the combined measurements of circulating insulin and C-peptide levels to reconstruct a function of proinsulin secretion. This calculation is based on a model validated by Watanabe in simulation experiments (59, 60) and extended to cover insulin recycling to the liver. The submodel for C-peptide kinetics is as follows:
where r 0 and r1 denote basal and dynamic insulin secretion, respectively, y1, y2 are the concentrations in the two C-peptide compartments, and Vcp is the volume of distribution in the central compartment. The differential equations describing the kinetics of the two insulin pools shown in Fig. 1 are described in the APPENDIX. Here, F(t) describes the fraction of the insulin input to the liver that passes through the liver and enters the systemic circulation. This function is modeled as an overlay of "radial base functions" that have a Gaussian normal distribution and that are shifted sequentially toward larger time values. Their positioning and individual widths are shown in Fig.  4 , top. Considering a constant basal value,
The hepatic insulin pool is small compared with the insulin pool in the systemic circulation (12, 30) and the amount of insulin imported via secretion and recycling. The size of the hepatic insulin pool rapidly adapts to the combined inflow of insulin and assumes a quasistationary state (53) . Insulin kinetics can thus be approximated using one compartment, for which the rate of change is
where V ip is the volume of distribution and DC(t) represents a time-dependent disposal coefficient. 
Here, ⌬nl serves as a nonlinearity factor. For ⌬nl ϭ 0, the extended coefficient is constant, and the resulting flux is a linear function of the insulin concentration. For a negative ⌬nl, the extended coefficient becomes smaller with increasing insulin concentration, leading to saturation at high concentrations. x m is used to scale the insulin concentration such that the power yields 1 for x ϭ xm. Metabolic indexes. Solving Eqs. 1-3 gives the time courses of plasma insulin, hepatic insulin transfer, and insulin secretion levels. These time courses enable assessment of the loss of secreted insulin concurrent with insulin passage through the liver and insulin excretion from the systemic circulation per time unit. Both processes are products of two time-dependent functions. To assess the contribution of, e.g., F(t), to the average hepatic loss of insulin, we defined average coefficients or process rates and required that their product with the average concentration or release equal the cumulative insulin secretion or disposal. In this sense, we defined FPR as the coefficient for the average hepatic first-pass removal, k H as the index for insulin disposal from the systemic circulation via the liver, and k I as the average peripheral disposal for a nonlinear disposal process. These variables are defined in detail as follows:
Identifiability of insulin disposal and hepatic transfer. Equation 3 defines a relation between the predicted insulin level x, the time derivative ẋ, the secretion function R(t), the disposal coefficient DC(t), and the hepatic transfer function F(t). The time course R(t) is primarily derived from C-peptide data, and the disposal coefficient and transfer function are adapted by optimization such that the predicted insulin levels and their changes approach the measured values. This optimization to match the time courses of x and R(t) should lead to a unique determination of the coefficients for insulin transfer and disposal. To explore the desired uniqueness, we took a set of ẋ,x,R(t),F(t) and parameters k I,kT values as fixed values derived from measurements that satisfied Eq. 3 for each time point. Next, we changed the parameters k I,kT by ⌬kI,⌬kT and considered a shift of the peripheral insulin disposal from a linear to a nonlinear process as described in Eq. 4 by setting ⌬k I,⌬nl to nonzero values and changing the time course of hepatic insulin transfer, denoted as G(t). This process yielded an altered insulin disposal coefficient of the following form.
G(t) was selected to compensate for any change in the parameters ⌬k I,⌬kT and ⌬nl such that Eq. 3 held for the altered and the original versions of the disposal coefficient for each time point:
With such compensation for parameter changes, a unique determination of insulin disposal and hepatic transfer is challenged. To explore the resulting leeway for parameter identification, we examined changes confined to the linear model, ignored changes in k T, integrated Eq. 7 over the sampling period, replaced the mixed integrals with the metabolic indexes defined in Eq. 5, and denoted the differences between the altered and original metabolic indexes as ⌬ to obtain
Equation 8 defines the change in the peripheral disposal coefficient necessary to compensate for changes in first-pass insulin removal and hepatic insulin disposal resulting from a given change in hepatic # Fig. 1 . Model structure. R(t): Pancreatic secretion of insulin and C-peptide in equal amounts; both substances reach the liver. From the hepatic pool, insulin is either lost by degradation with rate coefficient kL(t) or transferred to the systemic circulation. Here, it is lost via peripheral degradation (rate constant kI) or is recycled to the liver via liver blood flow. Following hepatic passage, C-peptide is distributed across two compartments and is cleared from the central compartment.
insulin transfer. However, the leeway for selecting these coefficients is limited, as the resulting hepatic insulin transfer, which is by definition the fraction of insulin that is cleared in one passage through the liver, must remain in the range of 0 to 1. Values near these boundaries only hold for the unlikely case that either all or none of the total insulin entering the liver is cleared. The hepatic insulin transfer parameter is used to define the coefficient for hepatic insulin disposal through recycling from the systemic circulation as k T[1 Ϫ F(t)]. Under basal conditions, this coefficient should approximately equal the peripheral coefficient kI (16) . Under glucose stimulation, hepatic insulin disposal should exceed peripheral insulin disposal (19) . Published estimates for transfer, basal disposal, and average disposal of insulin during stimulation are heterogeneous and occasionally conflicting. Published data on hepatic and peripheral disposal or transfer of insulin before and at the end of extended measurement protocols may differ but remain within the same order of magnitude. To define restraints for processes with time-dependent rates coefficients, such as the hepatic insulin disposal function or a nonlinear function of peripheral insulin disposal as described in Eq. 4, we use the metabolic indexes as defined in Eq. 5 for peripheral and hepatic insulin disposal. In this sense, we considered distinct ratios for different aspects of insulin transfer and disposal:
In addition, we required that deviations of insulin transfer from the basal rate approach 0 over time, or:
Ratios between two quantities typically remain in a range between 0.5 and 2.0. Hence, to avoid presumptions about absolute values for insulin transfer or disposal or about which particular process is more active, we assume that the likelihood of finding a specific ratio has an optimum of ϳ1 and a wide standard deviation, which corresponds to a tolerance range for a specific ratio.
In the following, we briefly summarize the key steps of MRA. Linear relationship between secretion and the concentrations of insulin and C-peptide. To cover multiple, pronounced changes in R D(t), the dynamic part of secretion, it is described as a polynomial of order 24 in time:
Let r denote values of RD(t) at specific time points; in our case, 25 different nodes or support time points, and let ⌿ denote a matrix containing power terms of the time variable at these nodes. Then, the secretion at the nodes is as follows:
Let zm be the vector of measurements of insulin and C-peptide concentrations, z be the vector of the calculated concentration at the nodes, and ż be the time derivative of z. The derivative is approximated using the differentiation operator D as ż Ӎ Dz (35) . Equations 1-3 are solved in the APPENDIX for diverging positions between nodes and sampling points to obtain the following:
Ms is assembled using ⌿, the differentiation operator D, and the reaction coefficients of the equation system 1 to 3. Regularization. The difference between the measurements and model predictions is z m Ϫ z, or zm Ϫ Ms ϫ w; therefore, this difference depends on the coefficients for the secretion polynomial. However, the large number of polynomial coefficients cannot be determined from the measurements via least squares regression. Furthermore, the differences could be small, with oscillation or overestimation of the predicted values between different nodes. To this challenge, the curvature of the secretion function is limited by constraining the size of the polynomial coefficients. A corresponding term is added to the target function for a least squares regression, extending the latter to a ridge regression (25) to obtain the following:
where ⌺ denotes the covariance matrix of the measurement errors. The ridge coefficient ␣ defines the relative weight of the restraining requirement and enables adjustment of the rigidity of prehepatic insulin secretion. Minimizing the fit norm with respect to the coefficient w gives the following:
where the m in wm indicates the minimal values based on the measured data. Minimizing Eq. 14 with regard to ␣ would drive ␣ to zero and induce large fluctuations in secretion. Equation 14 reflects the logarithm of a product of two likelihoods: P(Data|p,w,␣)P(w|␣).
Integrating this product over all polynomial coefficients yields a marginal likelihood, P(Data|p,␣), which reflects the probability of finding the measured data given the kinetic parameters and the rigidity ␣. The coefficients w are then converted to dependent variables that are estimated in an intermediate step using Eq. 15 from the measurements for a given set of p,␣. Not all of the latter parameters can be determined from the insulin and C-peptide measurements. Therefore, additional information regarding these parameters is provided in the form of a likelihood P(p) that defines the possible values for the parameters. This approach enables the definition of likelihood in a Bayesian sense for the parameters given specific data as follows.
The negative log-likelihood is minimized to find the parameters that best describe the data as follows:
where n is the order of the secretion polynomial.
Identification of parameters.
Parameters for the C-peptide subsystem were used as fixed values. Actual values were estimated using "van Cauter" formulas (57), which are based on age, sex, body surface area, and health status, i.e., "healthy" or "obese". In addition, the fixed volume of distribution for insulin, V ip, was assessed using a formula (7) based on age and body surface area, as Vip and kI cannot be identified separately based on insulin concentration data. The parameters k T,kI and r0,r1 for dynamic and basal insulin secretion, respectively (see Eq. 1), were estimated from OGTT data. As shown in the APPENDIX, kT was estimated from the ratio of liver blood flow (LBF) to Vip. At fixed Vip the adaptable parameter is LBF. To avoid negative values, these parameters were log-transformed for optimization and re-transformed for use in the model. The prior information for the parameters was expressed as log-normal parameter distributions. Their mean values are presented below with standard deviations in parentheses. Normal insulin clearance k I is in the range of 9 (1/h) (52) . For obese patients, lower values can be expected because of the inhibitory effect of free fatty acids on insulin clearance (65) . Therefore, a value of 6 (2.5-12) (1/h) was used for k i. The prior for dynamic secretion r1 was 700 (200-2,000) pmol/min, and that for basal insulin secretion r0 was 250 (90 -670) pmol/min. Their mean values were derived from Tura (56) . The prior for LBF was 1.5 (1.2-1.8) l/min (18) . The ratio restraints defined in Eqs. 9 and 10 theoretically span from zero to infinity, which can be described with a log-normal likelihood distribution to find a specific ratio. We assumed an optimum of 1 for these distributions and a standard deviation calculated from different tolerance ranges for a specific ratio. The restraining and prior distributions were added to the target function defined in Eq. 16.
Minimizing Eq. 17 to estimate p does not provide their confidence ranges. However, Eq. 16 has a form that is typically used in Bayesian statistics. In such a framework, parameter properties can be estimated via an iterative Markov-Chain Monte Carlo (MCMC) simulation. The following MCMC variant that determines step size and direction from a principal component decomposition of the covariance of the collected samples was used: algorithm 8 in Ref. 1 . The algorithm was implemented as an extension of the YADAS software package (23) . Convergence of the MCMC simulation chain was established with 5,000 burn-in samples followed by 15,000 iterations, using the Geweke criterion as implemented in the CODA software package (43) .
Use of published mean population values. Mean plasma insulin and C-peptide concentrations across a juvenile obese population were obtained from published data (51) . The corresponding figures were digitized, and pixel coordinates were then converted to time and concentration values. Independent replicated conversions produced imprecision in the converted values of ϳ1-2% of the nominal values. The error in these mean values was assumed not to correlate with a signal-dependent standard deviation. The corresponding scaling factor was found to be ϳ0.02 and 0.03 for C-peptide and insulin, respectively, by minimizing the MRA target function with respect to the scaling factor and other model parameters.
Quality of fit for the collocation approach. A simulation was used to assess how well the secretion profile could be reproduced: Eqs. 2-4 were solved via standard numerical integration (63) for a predefined insulin secretion profile based on an inverse Gaussian distribution (62) and predefined kinetic coefficients. This calculation produced a time profile of plasma insulin and C-peptide levels. These profiles were used as a reference together with the secretion profile and the initial coefficients. Synthetic concentrations were generated by taking selected samples from the reference profiles. For the simulation, the synthetic concentrations were used together with the reference coefficients to assess the secretion coefficient w m using Eq. 15. wm was then used in Eqs. 12 and 13 to reconstruct the secretion and concentration values. The MRA used 29 time grid points and a polynomial order of 30. For comparison, self-developed implementation of the stochastic deconvolution (13, 49) was used to reconstruct unknown secretion profiles using the same set of concentration data, model system and kinetic coefficients. An equally spaced virtual grid of 600 time points over 5 h was used.
Nonlinear peripheral disposal. MRA analysis of the population data produced a secretion function that led to a best match of model prediction to the plasma hormone measurements. This secretion distribution was fixed together with the degree of nonlinearity in peripheral disposal. For these predefined values, the insulin model consisting of differential Eqs. 2-4 was solved by implementing numerical integration procedures (63) and was fitted to the insulin and C-peptide concentrations as well as the restraints defined in Eqs. 9 and 10 using a parameter optimization routine (44) . This resulted in an optimal transfer G(t), which was used together with the secretion curve and the predicted time course of plasma insulin levels to assess the metabolic indexes for the nonlinear case.
Study population. A cohort of n ϭ 135 markedly obese Caucasian children and adolescents was recruited from the Obesity Clinic of the Division of Pediatric Endocrinology and Diabetes, Dept. of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany. Subjects were eligible if they were healthy, were between 8 and 19 yr of age, and had a BMI beyond the 97th %ile based on German reference data (28) . Baseline blood samples were obtained at 0800 after a 12-h overnight fast, followed by a standard 75-g OGTT. The sampling time points for the measurement of plasma glucose, insulin, and C-peptide levels during the OGTT were 0=, 15=, 30=, 60=, 90=, 120=, 150=, and 180=. The Institutional Review Board of the University of Ulm approved all of the study proceedings.
Biochemical analyses. Plasma glucose was measured using the hexokinase method with a Roche Cobas 6000 analyzer system (F.
Hoffmann-La Roche, Basel, Switzerland). Plasma insulin and C-peptide concentrations were measured using immunoassays (ECLIAs) with a Roche Cobas 6000 immunoassay analyzer system (F. Hoffmann-La Roche). The coefficients of variation in two-level controls were below 2% for all applied assays.
RESULTS
We propose the application of the MRA to assess insulin secretion and disposal among obese adolescents during an OGTT. Therefore, we first explored whether the MRA is the appropriate tool and whether the proposed model structure could be applied on the target population. Next, we assessed whether our strategy to ameliorate parameter nonidentifiability by imposing restraints succeeded under a sparse sampling protocol. Finally, we applied the model to obese juveniles to determine whether it could produce reliable results.
Quality of the MRA approximation. We approximated prehepatic insulin secretion using polynomials, expressed the concentrations of insulin and C-peptide at different time points (collocation) as a linear function of the polynomial secretion coefficient, and restrained the curvature of the polynomial via regularization. To test the quality of this collocation/regularization-based approximation, we reconstructed prehepatic insulin secretion and plasma insulin concentrations from errorfree reference measurements. The reference measurements were simulated from reference prehepatic insulin secretion values, as indicated in Fig. 2 (solid line) , and reference kinetic coefficients determined from published population mean values, which are shown in Table 1 . The difference between the reconstructions and the corresponding reference values was used as a measure of the approximation quality. In addition, the secretion function was estimated via stochastic deconvolution using the same coefficients and simulated hormone concentrations. Figure 2 indicates a comparable quality in reconstruction. Moreover, for the MRA, three matrix multiplications and one singular value decomposition was necessary for matrix dimensions of ϳ30 ϫ 30. For the deconvolution, a similar effort of two matrix multiplications and one singular value decomposition was necessary; however, more than 100 repeated numerical integration runs were also needed for the insulin system using the deconvolution method, and this cal- culation required considerably more time. Therefore, collocation can replace deconvolution.
Reference system for obese adolescents. The model structure proposed in Fig. 1 should hold for a population of obese children and adolescents. For validation, the MRA approach was applied to corresponding published mean data using a mean tolerance range of transfer restraint ratios from 0.5 to 2. Figure 3 shows the model fit to the insulin and C-peptide concentrations and the resultant estimated prehepatic insulin secretion levels. In Fig. 4 , the solid line shows the corresponding hepatic insulin transfer rate. The plasma insulin and C-peptide data were not sufficient for a simultaneous determination of coefficients for hepatic transfer and peripheral and hepatic disposal. As a solution, we applied restraints to hepatic transfer under basal conditions, the ratios of hepatic to peripheral disposal under basal conditions, and the ratios of unstimulated to stimulated disposal values. We explored different tolerance levels for these restraints, beginning from a wide (0.33 to 3) to moderate (ratio range 0.6 to 1.666) range, with a mean ratio set to 1. Each restraint level was analyzed using an MCMC approach, which provided mean values and 95% confidence ranges of the determined parameters and the secretion function. Table 1 shows the resulting precision and accuracy of key metabolic parameters for three tolerance levels and the impact of the sampling frequency and protocol duration on estimates for disposal and secretion. We imposed a restraint of 0.5 for the mean hepatic transfer rate (q 0 in Eq. 9). The fifth column of Table 1 shows the determined values for this parameter, and the first three rows show the q 0 values for a stepwise relaxation of the restraints. These values move away from the desired values toward higher values. The same tendency was observed for a 4-h sampling regimen, but the values were slightly closer to the reference value. For the shorter protocol, the number of sampling points was reduced by two, which increased the relative weight of the restraints, and the corresponding values for q 0 were closer to the target values of the restraints. Hence, the q 0 values reflect the effectiveness of the restraints. The q 0 values also control the metabolic indexes. Based on Eq. 5, increasing hepatic transfer decreases first-pass removal, and we found a negative linear relation with R 2 ϭ 0.99 between first-pass removal and mean hepatic transfer across the different restraint levels for a 4-or 5-h protocol. Reducing first-pass removal increases the left side of Eq. 8; consequently, the amount of secreted insulin transferred to the circulation is increased. This alteration is reflected by increases in the total disposal coefficients. Increasing hepatic transfer also decreases hepatic disposal on the right side of Eq. 8. Here, we found a strong correlation with R 2 ϭ 0.93 between the q 0 values and the hepatic disposal coefficient. To cover the increased amount of transfer, peripheral disposal increased, as demonstrated in Table 1 . Therefore, the ratio of hepatic to peripheral disposal is sensitive to the efficiency of the restraints. Changing hepatic transfer affects both first-pass removal and hepatic clearance, and Eq. 8 defines how the peripheral disposal changes to balance input into and loss from the peripheral circulation. These considerations hold for a 4-or 5-h sampling protocol. For the shorter, routine "3-h, 8-sampling-point protocol", we observed the same sensitivity against the restraints. However, the actual values were slightly different; i.e., the total disposal coefficient for comparable hepatic transfer was lower for the 3-h protocol than for the extended protocols. Figure 3 provides an explanation for the observed differences. Within the first 3 h, secretion and transfer of insulin to the systemic circulation are nearly complete. Thus, cumulative transfer ranges slightly below the 5-h value. Hence, the calculated total disposal rate changes only marginally to maintain the balance between insulin disposal and the secretion into the systemic circulation. As the disposal rate is a product of larger average insulin concentrations and the disposal coefficients, these disposal coefficients remain lower to maintain a balance.
Equation 7 indicates that, once a satisfying fit to the data is obtained from a linear model, one can use the predicted secretion, hepatic transfer, and insulin concentration values to generate a comparable fit to measured concentrations using a model of saturable peripheral disposal. This model provides the basis for optimizing the coefficients for nonlinear peripheral and hepatic disposal such that the restraints imposed for hepatic transfer are optimally met. Figure 4 , inset, bottom, shows the estimated nonlinear disposal as a function of the insulin concentration, which clearly deviates from the linear Table 1 show the estimates for disposal and secretion for mild and pronounced saturation of peripheral disposal; these estimates were comparable to those in the linear case. Insulin levels were high in the first 1-2 h of the experiment and drove peripheral loss of insulin to saturation, leading to an underestimation in the nonlinear model compared with the linear case. Figure 4 shows the differences in hepatic transfer between the linear and nonlinear models. For the nonlinear model, in the first phase, in which peripheral disposal was saturated, hepatic transfer was reduced, and secretion and disposal thus remain balanced. Subsequently, the insulin levels approach low to normal values, and this change was associated with a relative overestimation of disposal. In this subsequent phase, hepatic transfer was increased. Averaging across both phases yielded a disposal that is comparable between the linear and nonlinear cases.
Application to obese adolescents. Data from 135 patients who underwent a 3-h OGTT with eight sampling points were analyzed. The measurement error was considered to be 3% of the nominal value. The MRA target function of Eq. 16 was optimized to obtain coefficients that would provide the optimal fit to the data from an individual patient. Across all patients, the average-fit error, reflecting the sum of the weighted deviations of the concentration predictions to measurements and of the weighted deviations of the parameters from restraints, was ϳ25, with heavy tailing to the left, and the corresponding fit error distribution peaked at 10. Heavy tailing is typical for a 2 distribution pertaining to a sum of squared errors. Figure 5 shows examples for patients with different manifestations of a first-phase insulin secretion defect, which implies that the defect can be detected if present. The 95% confidence ranges for the secretion function indicate a reliable determination of secretion. Figure 6 shows insulin secretion levels plotted pairwise against hepatic and total insulin disposal. The top left corner of Fig. 6 displays the conditions expected for healthy patients. Secretion and clearance were inversely correlated. The ellipses indicate the 95% confidence range for joint determinations of secretion and disposal. The determinations for a patient with low secretion were well separated from the determinations for patients with moderate or high secretion.
DISCUSSION
We propose a method to determine insulin secretion and degradation rates from insulin and C-peptide concentrations collected during an OGTT with sparse sampling. Our model is built around basic physiological principles such as the understanding that secretion generates insulin and C-peptide in equal amounts and that insulin recycles between the liver and the systemic circulation and can be disposed of from both compartments. Uncertainties regarding detailed molecular mechanisms or a lack of appropriate observation points are centered on secretion and hepatic metabolism; therefore, these processes were described as time-dependent functions without any reference to underlying mechanisms. The number of coefficients secretion (pmol/min) total disposal coefficient (1/hr) overweight obese extremely obese Fig. 6 . First-pass removal (top) and total insulin disposal (bottom) as a function of total insulin secretion, which reflects the cumulative basal and dynamic secretion over the oral glucose tolerance test (OGTT) period. Ellipses indicate 95% confidence ranges of a joint determination of first-pass removal or total disposal and secretion of insulin for 2 individual subjects. and parameters necessary to describe two time-dependent functions and other model components approaches the number of measurements, and this limitation challenges the identifiability of these unknowns. Furthermore, we found that the unknowns cannot be uniquely determined based on insulin and C-peptide concentration data alone. As a solution, we applied general behavioral specifications and required that the model prediction for hepatic metabolism and its activity relative to peripheral metabolism should approximately match the earlier observed relations. Using these restraints, total insulin disposal could be assessed. To assess any potential bias caused by sparse sampling, published data from an obese population were analyzed. We discuss whether such a concept can provide reliable, unbiased results.
Technical details. In our MRA approach, we describe insulin secretion over time using a polynomial function and use a nonstandard solution of differential equations to define a linear relation between the secretion coefficients and the predicted concentrations of the secreted compound. This relation is used to define a likelihood of obtaining a specific data set. For this likelihood, the coefficients for the secretion polynomial are marginalized or integrated out. The coefficients are calculated in an intermediate step as functions of the parameters pertaining to kinetics and rigidity. The marginalized likelihood therefore depends only on parameters pertaining to kinetics and rigidity or regularization, and only these parameters are determined by optimizing the likelihood. For optimal rigidity and kinetic coefficients, the secretion coefficients can be determined according to the calculations of the intermediate steps.
To explore how well our approach could reconstruct a given secretion profile in the ideal scenario, we approximated secretion coefficients from synthetic measurements and used these coefficients to reconstruct secretion profiles and plasma concentrations. The differences between the reference profiles and the profiles reconstructed under optimal conditions with correct kinetic coefficients and error-free measurements were negligibly small and comparable to those obtained via stochastic deconvolution (13, 49) ; this finding was in line with our previous research using the MRA (58). For low rigidity, the values for secretion are assumed to best fit the predicted concentration values for the measurements, with a large interpolation error occurring between the sampling points. With increasing rigidity, the interpolation error improves, and the fitness of the estimates to the measurements worsens. These opposing trends between fit error and interpolation error require optimization of rigidity to find a good compromise. Such a compromise was obtained; however, it showed a bias toward smoothed secretion. Stochastic deconvolution also allows an automated optimization of the smoothness of secretion using a slightly different criterion. Here, the number of efficient parameters needed to define secretion should match the penalty for "nonsmoothness". Estimation based on such a criterion is closely related to "Bayesian evidence" estimation (34), and our marginalized and regularized estimation belongs to this class of approaches (2); therefore, the criterion used in stochastic deconvolution was also met by the MRA at optimal smoothness. However, using the MRA, this criterion was met as a side effect of optimizing the target function defined in Eq. 16 . The target reflects a probability and can therefore be easily imbedded into general Bayesian approaches for parameter determination. Consequently, reliable joint confidence ranges of all determined parameters can be assessed using MCMC simulation.
Imposition of different restraints. Imbedding into Bayesian estimation was important, as we encountered identification problems for parameters pertaining to disposal and hepatic transfer of insulin. Equation 8 defines a line or subspace of nonidentifiability. The actual positioning on this line cannot be assessed from the insulin and C-peptide concentration data alone but can be approximated based on general physiological considerations. The permissible range of substance transfer is restricted, and according to the literature, the rates of peripheral and hepatic disposal from the systemic circulation are of the same order of magnitude. These observations were used to define mild restraints on the ratio of hepatic loss to hepatic transfer and the ratio of hepatic to peripheral disposal. As long as these ratios were constrained within the range of 1/3 to 3, these restraints did not impose a relevant prejudgment on the estimates of total disposal. A wider range was not explored, as using a wider range would imply close-to-zero values for either peripheral or hepatic disposal and because the tolerance range used for restraint was sufficiently wide to cover a variety of health states. Kidney clearance is a major component of peripheral disposal (18) and is operative as long as the kidney functions. In healthy adults, hepatic disposal exceeds peripheral disposal under glucose stimulation (16) at a supposed ratio of ϳ80:40, or 2.0. We assumed that for young obese subjects hepatic disposal could be reduced in an extreme case to one quarter of its normal value, leading to a ratio of 20:40, or 0.5, and this value remained within our tolerance range. Similar considerations held for other ratio restraints, e.g., the fraction of insulin input into the liver cleared via metabolism relative to the fraction transferred to the circulation, and for hepatic transfer, which should be ϳ0.5. We applied these restraints on the population studied by Sunehag et al. (51) . This population was similar to the population on which we focused, but the OGTT sampling period in the former study was 2 h longer, and more sampling points were used. We found that ϳ34% of the secreted insulin was cleared on the first pass through the liver. Another 27% of the secreted insulin was cleared in the liver after recycling from the periphery, leading to a total of 62% of the secreted insulin mass that was cleared by the liver. Only ϳ38% of all insulin was cleared from the periphery, and the corresponding disposal coefficient was in the range of the disposal coefficient for C-peptide, which reflects renal clearance. Thus, hepatic clearance dominates the system. Direct measurements of hepatic first-pass removal based on the hepatovenous/arterial difference produced greater values than our observation of 35% clearance via hepatic first-pass removal. For example, Meier (37) reported 80% first-pass clearance of insulin in healthy humans. However, these results were obtained during a constant intravenous infusion of glucose and therefore cannot be transferred to the physiological situation of a 75-g oral glucose challenge. On an OGTT, the same authors reported a 60% reduction in hepatic insulin clearance (36) , and this reduction could not be attributed to incretin effects. This finding indicates that high portal glucose levels per se may inhibit hepatic insulin clearance, and this process has also been demonstrated in vitro (41) . As a rough estimate, the 80% first-pass removal observed under conditions of intravenous infusion of glucose can be reduced to 50% first-pass removal under conditions of an OGTT. Obesity itself may further reduce hepatic insulin extraction due to increased levels of free fatty acids (40) , which suppress insulin receptor binding and internalization (16) . Furthermore, the observation of reduced hepatic CEACAM1 expression in obesity (32) may provide a potential molecular mechanism for further reducing hepatic insulin clearance (45) via impairment of hepatic insulin degradation and induction of insulin resistance as a result of increased triglyceride formation (39) . If the obesity-induced reduction in insulin clearance reaches 60% of the normal, healthy OGTT level, then we arrive at the 35% first-pass hepatic clearance that we observed in the present study. Therefore, we believe that a reduction of first-pass removal in obesity to ϳ35% of the total secreted amount of the substance is consistent with the literature.
Reduced sampling and model misspecification. We obtained a good fit of the model predictions to the measurements obtained from the population studied by Sunehag et al. (51) . Using 18 measurement points for insulin and C-peptide concentration values, the number of measurements exceeds the number of unknowns. Therefore, overfitting due to an insufficient number of data points is unlikely, and the data can be explained by the proposed model structure. The sampling was sufficiently dense to analyze two key features: the bias induced by reduced or sparse sampling, and potential misspecification of peripheral insulin disposal. With reduced sampling, the standard deviation in estimated total disposal increased from 6.5% to 9% of the nominal value. The corresponding error in the determination of peripheral disposal remained in the range of 25%. Compared with the 5-h estimates, the estimates for total disposal using the reduced sampling method were reduced by ϳ10%. This difference can partially be attributed to the restraints, which become more important for a reduced number of measurements. These effects are exacerbated by averaging across a shorter time frame, which ignores the later phases of an OGTT test. Therefore, the metabolic indexes can be compared only when performing calculations over the same time span.
Under dense sampling, insulin secretion can be estimated from C-peptide data alone. We used the estimated secretion as a given input into an insulin model and assessed the kinetic coefficients for a pronounced saturable peripheral disposal. However, the estimates from the corresponding averaged indexes for disposal were similar to the estimates from the linear model. This result is counterintuitive, as saturation implies that higher concentrations are required to dispose a given insulin amount, which should in turn be reflected by a smaller disposal coefficient. However, the results in Fig. 4 indicate that for insulin concentrations near basal values the nonlinear rate of disposal is higher than the linear rate, and for insulin concentrations above 200 pmol/l the nonlinear rate of disposal is lower than the linear rate due to saturation. For the average reference obese subject (51), the insulin concentrations were above these levels in the first half of the 5-h OGTT test period and below these levels during the second half; therefore, the phases of over-and underestimation balance out, leading to a total disposal coefficient near the linear values. In the first phase of high secretion, when saturation comes into play, the hepatic disposal rate is lower; however, subsequently, at lower insulin concentrations, the disposal rate is slightly higher such that the average amount disposed at a given concentration remains comparable. Insulin concentrations remain the same because in the first phase, when the disposal rate is lower, the hepatic transfer rate is also lower; conversely, in the second phase, when the insulin secretion rate is lower, the hepatic transfer rate is higher than in the linear case. Therefore, the changes in the time course of hepatic transfer can compensate for the saturation effects. Due to the interplay between disposal and hepatic transfer, the metabolic index for total disposal is robust despite the individual processes not being determined with high precision. As a result, the coefficient for average total disposal appears to be robust against misspecification of the detailed disposal mechanism. Hepatic insulin metabolism and secretion are described as nonparametric components, which by definition cannot be subject to misspecification. The remaining model component was insulin recycling between the liver and the systemic circulation, and for simplification we adopted the sole "not-validated" assumption that the intrahepatic insulin concentration rapidly adapts to concentration changes in blood supply to the liver, based on the understanding that the amount of insulin in the hepatic vascular bed is small compared with the amount transported through the liver via blood flow (30) . In summary, the present model used only one unvalidated component, peripheral insulin disposal, and any misspecification of this parameter did not impose any significant bias.
Application to patient data. We detected high variability of insulin secretion and degradation in obese adolescents. Approximately 20% of the subjects displayed secretion and clearance rates comparable to those of healthy adults. For the remaining patients, insulin clearance was decreased, which could be attributed to reduced insulin binding and internalization as described above. The inverse correlation between insulin clearance and secretion, as shown in Fig. 6 , may reflect a compensatory response to insulin resistance, a finding that has previously been shown in obese adults and obese adolescents (40) . This evidence mirrors the inverse relation between "metabolic insulin clearance" and first-phase secretion observed under conditions of metabolic syndrome (42) . Reducing insulin clearance increases the insulin concentration, which is further increased by concurrently elevated insulin secretion. Compared with the data for healthy subjects, our estimates for total disposal as derived from published data were somewhat below the mean values; however, values estimated for our patient population were substantially lower. Moreover, the negative correlation between insulin secretion and insulin disposal has been reported in many other studies (31, 33) . The major component of a principal component analysis of the determined kinetic coefficients involves insulin clearance and, in the opposite direction, insulin secretion. This component is not based on measurement error during parameter determination. The corresponding uncertainty, as estimated from MCMC simulation, has a predominant direction that is nearly diametrically opposed to the major principal component. The uncertainty in the direction of the major principal component is small compared with the intersubject variation of the data, which would enable the staging or classification of an individual patient according to the position on the axis of the main principal component as derived from OGTT data. In our study, we imposed restraints for the kinetic coefficients based on published values. By using more than 100 patients, individual parameters could also be restrained to the range defined by population characteristics. On the basis of the results in Fig. 6 , we expect that these ranges can be greatly reduced, which should lead to more precise individualized estimates. The target function defined in Eq. 17 already has the form required for a population-based Bayesian analysis. Moreover, the reduced numbers of parameters that are optimized support such an undertaking. To date, only insulin and C-peptide concentrations derived from an OGTT have been analyzed. An additional analysis using the "minimal model of glucose" would enable an assessment of the disposition index (11) from dynamic insulin sensitivity, insulin secretion, and variations in glucose concentrations, all of which can be obtained from OGTT data. However, only the total disposition can be calculated, because our analysis does not discriminate between the dynamic and static effects of glucose on secretion. The results in Fig. 4 suggest that first-phase insulin secretion can be determined using our sampling and modeling approach, but this will require further validation by alternative approaches and an extension of this study to isolate the first-phase response. In summary, we introduced a novel approach to assess the metabolism of insulin from OGTT data with sparse sampling, explored the first application of this approach to obese children and adolescents, and outlined the potential of this approach for the comprehensive characterization of individual patients.
In summary, when insulin and C-peptide concentration data are combined with mild restraints, the coefficients for total disposal can be reliably determined. Estimation of hepatic transfer and separation of peripheral disposal from hepatic disposal are feasible; however, these calculations depend on the prior assumption posed to define the restraints and are therefore less reliable.
APPENDIX
Elements of the MRA approach. To derive the key MRA equation Eq. 13, let u denote the plasma concentration of the substance in a single, well-stirred pool with a first-order removal and an unknown, time-dependent input R(t). The differential equation describing such a system is as follows:
Let u denote the vector of u(t) at n ϭ 25 different time points or nodes that cover the time range of interest, and let u be the vector of the time derivative at these nodes. This can be approximated according to Mason and Handscomb (35) as u Ӎ Du. Mason and Handscomb show that this approximation is optimal if t is transformed to be in the range of Ϫ1 to 1 and the nodes are positioned at the extrema of a Chebyshev polynomial of order n. With this approximation, the left part of Eq. A1 is as follows:
where I is the identity matrix. R(t) is approximated as a polynomial of order (n Ϫ 1) in time with polynomial coefficients wi. If r denotes actual values of R(t) at the nodes, these values can be expressed as follows:
where ⌿ contains the power terms of the time variable at the different nodes. The differential equation defined in Eq. A1 can then be expressed as follows:
Let um be the vector of concentration measurements, sampled at time points that differ from the nodes used for an approximate solution of Eq. A1. In Ref. 58 , we establish a linear relationship between the measured concentrations and values at nodes in the form of u m ϭ Mtransu, and Eq. A4 transforms to
With Eqs. A2-A5, a differential equation with unknown input R(t), is converted into a matrix equation that defines a linear relationship between the measured concentration values and the polynomial coefficients for the unknown release, R(t). Equation A5 could be used in a linear regression to assess the coefficient from the concentration measurements, provided that the kinetic coefficients are given. However, the number of measurements is smaller than the size of w m. This underdetermination is accounted for by two measures: first, the coefficients of R D(t) are regularized by minimizing their squared sum, which leads to Eq. 14, which corresponds to the target function of a ridge regression (25) . Moreover, we restrain the left and right boundaries of the polynomial for R D(t) and require for the left boundary that R D(0) and its first time derivative are zero and that derivatives up to the 5th order are close to zero, whereas for the right boundary we generated a set of different synthetic release curves, all decaying at the right border, and required that R D(t) approach the mean values within the frame of the standard deviations. In addition, we required that ͐ R D(t) ϭ 1 over the experimental time frame. These restraints can all be expressed as linear functions of w m and can be used as additional "pseudo"-measurements or to reduce the size of w m by expressing a few elements as a function of the remaining unknown elements. For further details, see the APPENDIX of the original MRA paper (58) .
Rate of change of insulin concentration. Let L p,xp be the insulin amount in the hepatic vascular space and in the central blood pool, let L,x be the corresponding concentration values, and V L,Vip the volume of distribution in these two compartments. We consider a system of differential equations describing the changes in the pool sizes of insulin in the hepatic vascular space an in the systemic circulation, and the corresponding insulin mass fluxes are described as a product of coefficient times concentration or hepatic blood flow (HBF) times concentration. The rates of changes of the insulin mass in the two compartments, assuming a general model structure as shown in Fig. 1 are:
To obtain a system of differential equations with concentrations a state variables both sides of Eq. A6 are divided by the appropriate volume of distribution, which gives:
The hepatic vascular space is in the range of 300-1,000 (12, 30) and the remaining central blood volume about 5.5 liters; hence, V L is about 5-15 times smaller than V ip. On the right side of the equations above, the net fluxes are multiplied by the inverse of the distribution pool sizes, which for the liver is about 5-15 times larger. Hence, the insulin amount in vascular space of the liver will quickly adapt to the secreted amount R(t) and the amount recycling from the systemic circulation, and one can assume quasi-stationary that yield a quasi-stationary state for the hepatic insulin concentration (53) Replacing L in the equation describing the change in the insulin concentration with the term defined in Eq. A8, performing in the
